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a b s t r a c t
The mammalian urogenital sinus (UGS) develops in a sex speciﬁc manner, giving rise to the prostate in
the male and the sinus vagina in the embryonic female. Androgens, produced by the embryonic testis,
have been shown to be crucial to this process. In this study we show that retinoic acid signaling is
required for the initial stages of bud development from the male UGS. Enzymes involved in retinoic acid
synthesis are expressed in the UGS mesenchyme in a sex speciﬁc manner and addition of ligand to
female tissue is able to induce prostate-like bud formation in the absence of androgens, albeit at reduced
potency. Functional studies in mouse organ cultures that faithfully reproduce the initiation of prostate
development indicate that one of the roles of retinoic acid signaling in the male is to inhibit the
expression of Inhba, which encodes the βA subunit of Activin, in the UGS mesenchyme. Through in vivo
genetic analysis and culture studies we show that inhibition of Activin signaling in the female UGS leads
to a similar phenotype to that of retinoic acid treatment, namely bud formation in the absence of
androgens. Our data also reveals that both androgens and retinoic acid have extra independent roles to
that of repressing Activin signaling in the development of the prostate during fetal stages. This study
identiﬁes a novel role for retinoic acid as a mesenchymal factor that acts together with androgens to
determine the position and initiation of bud development in the male UGS epithelia.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
Introduction
The prostate develops from the urogenital sinus (UGS), an
endodermal structure derived from the cloaca. The UGS has a
bipotential fate depending on the sex of the embryo and will
differentiate into the prostate and bulbourethral gland in males or
contribute to the vagina during development but not in the adult
in the female (Kurita, 2010; Marker et al., 2003). This sexual
differentiation is driven by the presence or absence of androgens.
In males, the production of hormones by the fetal testis ensures
the development of secondary male speciﬁc structures, including
the prostate. Two types of tissue are present in the UGS; the
epithelium (UGE) and the surrounding mesenchyme (UGM), and
prostate development depends on their interaction (Cunha, 2008).
The UGM has been shown to specify prostate identity on epithelium
from different sources, including bladder (Cunha et al., 1983).
Androgens signal through the androgen receptor (AR) and analyses
of tissue recombinants with tissue from AR deﬁcient mice have
shown that mesenchymal AR is required for prostate formation
from the UGS (Cunha and Lung, 1978).
Prostate development is initiated in response to androgens
with the UGE budding out and growing into the surrounding
mesenchyme. In the mouse this occurs in the fetal period at
around E16.5–17.5 (embryonic day 16.5–17.5). The buds then
elongate, branch, canalize and cytodifferentiate to become secre-
tory at 12–20 days after birth. The initial steps of bud development
are faithfully reproduced in ex vivo organ cultures and these have
been used to determine the factors involved in prostate differ-
entiation (Doles et al., 2005; Lopes et al., 1996). However, the
molecular pathways involved in prostate development initiation
are poorly understood. One factor that has been identiﬁed to be
important is FGF10, which is produced by the UGM in both sexes
(Thomson and Cunha, 1999). Mice that are deﬁcient for FGF10
show rudimentary prostate bud formation that does not progress,
even in the presence of androgens (Donjacour et al., 2003).
The vitamin A derivative, retinoic acid (RA), has been implicated
in many processes during embryogenesis. In the prostate, RA has
been shown to increase prostate budding at embryonic stages but
has also shown to inhibit prostate ductal growth and branching at
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postnatal stages (Aboseif et al., 1997; Seo et al., 1997; Vezina et al.,
2008). The levels of the highly biologically active RA are tightly
controlled in the embryo in space and time. The dietary form of
vitamin A, retinol, is converted to RA in two steps catalyzed by two
types of enzymes, the alcohol dehydrogenases, ADH, which are
widely expressed, and the aldehyde dehydrogenases, ALDH, with
restricted expression patterns. The presence of RA is further
restricted by inactivation through metabolizing enzymes such as
those belonging to the CYP26 family. RA acts as a ligand for the
retinoic acid receptors (RARs) that bind DNA together with the
retinoic X receptors (RXRs) at speciﬁc retinoic acid response
elements (RARE) and contribute to transcriptional control.
In this study we show that RA, synthesized in the male UGM in
a sex speciﬁc manner, is required for the initial step of prostate
formation from the UGS. Addition of RA is able to induce prostate
bud formation in the absence of androgens, albeit at reduced
potency. Expression and functional analysis revealed that one of
the roles of RA is to repress the production of Activin by the UGM
that inhibits prostate bud formation. Our study suggests that the
combined action of androgen and RA determines early prostate
development in the UGE.
Methods and materials
Mouse strains
All mouse work was carried out in accordance with the UK
Animals (Scientiﬁc Procedures) Act 1986. Female MF1 outbred
mice were purchased from Harlan UK Ltd. at 6–8 weeks old and
mated with male MF1 outbred mice to obtain wild type embryos.
For embryo staging, observation of a vaginal plug was designated
as embryonic day 0.5 (E0.5). RARE-LacZ mice were generated by
Janet Rossant and were kindly provided by Peter McCaffery,
University of Aberdeen (Rossant et al., 1991). Inhba/ (Inhba
mutant) animals lacking the Inhba coding sequence were main-
tained through heterozygote breeding because Inhba mutants are
neonatal lethal, as previously described (Matzuk et al., 1995).
UGS organ culture
Fresh UGS tissue was dissected from embryos in PBS by removing
the bladder, urethra and ductal tissue using a 5 mm dissection knife,
as previously described (Staack et al., 2003). Female UGS were used
for all experiments, as they have not been exposed to fetal andro-
gens. Similar organ culture results were also observed when using
male UGS, although the degree of prostatic inhibition was variable.
This variability was probably due to the presence of older embryos
where prostate budding had already initiated at the time of dissec-
tion. UGS samples from E15.5 female embryos were chosen because
of consistency of bud growth in culture. Similar results were
obtained when E14.5 embryos were analysed. To grow tissue caudal
to the prostate, the bladder and UGS were identiﬁed and the
surrounding tissue carefully dissected with forceps until the tissue
that will form the bulbourethral gland was located. A dissection knife
was then used to remove the prostate and the bulbourethral gland
and the intermediate tissue was used for culture. Dissected tissue
was grown on 0.4 μm Biopore ﬁlters (Millipore, UK) in 2.5 ml of
serum-free culture medium (DMEM/Hams F12 1:1) containing 1 x
ITS (insulin, transferrin and sodium selenite) (Sigma, UK), 0.025 mg/
ml gentamicin (Sigma, UK), 0.06 mg/ml benzylpenicillin sodium,
0.1 mg/ml streptomycin sulphate and 0.05 mg/ml ampicillin. Dihy-
drotestosterone (DHT) (Sigma, UK) was solubilised in 100% ethanol
and added to the media at a concentration of 10‐8 M. All trans
retinoic acid (RA) (10‐6 M), the ALDH inhibitor 4-diethylamino-
benzaldehyde (DEAB) (50 μM), the pan RAR inverse agonist
BMS493 (20 μM) and the activin inhibitor SB431542 (50 μM) were
prepared in DMSO and added to the media (Sigma, UK). Control UGS
were treated with the equivalent volume of vehicle. The dishes were
placed in a humidiﬁed incubator at 37 1C in 5% CO2 and media was
changed at least every 48 h.
Bud number quantiﬁcation
Bud number counting was performed on whole mount in situ
stained UGS samples or from sections of Inhba mutants and
controls. Positive buds were deﬁned as those that stained for
Nkx3.1 (Figs. 2A–C, 4C–E, and 5), were clear bud-like structures on
a light microscope (Fig. 2D) or by histological features with
haematoxylin and eosin staining (Fig. 4A). Statistical signiﬁcance
when two treatments were compared was calculated using the
Student’s two-tailed T-test.
Real-time PCR (RT-PCR)
RNA was extracted from tissue using an RNeasy Micro kit
(Qiagen). cDNA was synthesized using OligodT primer and Super-
scriptII Reverse Transcriptase (Invitrogen). mRNA accumulation of
Aldh1a1, Aldh1a2, Aldh1a3, Fgf10, Inhba and Hprt1 mRNA was
determined using the TaqMan system (Applied Biosystems, UK).
Triplicates of each sample were analysed. Relative gene expression
was calculated using the ΔΔCt method and the housekeeping
gene Hprt1 as the normaliser. Statistical signiﬁcance was calcu-
lated using the Student’s two-tailed T-test.
Whole mount in situ hybridization analysis
In situ hybridization was carried out on an in situ processor
(Intavis In Situ Pro) using a standard protocol as described
previously (Val et al., 2006). Digoxigenin-labelled antisense RNA
probes for Aldh1a1, Aldh1a2, Aldh1a3 and Inhβa were generated
from PCR fragments containing T7 RNA polymerase recognition
sites using the following primers.
Aldh1a1:50AGCTCAAGACAGTCGCAATG30 and
50GTAATACGACTCACTATAGGGAGTCCTCCTCACCAAATGAG30
Aldh1a2:50TGCCAAGACTGCCACGTTTC30 and
50GTAATACGACTCACTATAGGGAAGGACTCAAAGCCACTGTC30
Aldh1a3:50GGCTAACAAGTAACACCTGG30 and
50GTAATACGACTCACTATAGGGCCTCCGTGTACTTACAGCTA30
Inhβa: 50ATT TGCTGAAGAGGAGAAGG30 and
50GTAATACGACTCACTATA GGGCGGCAAAGGTGATGATCTCC30
Probes for Nkx3.1 and Sox9 have been described previously
(Bhatia-Gaur et al., 1999; Thomsen et al., 2008). Stained whole-
mount in situ hybridization samples were ﬁxed in 4% paraformal-
dehyde, taken through a sucrose gradient before being frozen in
OCT (R.A. Lamb) at 80 1C and then sectioned.
β-Galactosidase stain
Transgenic embryos and organ cultures expressing RARE-LacZ
were ﬁxed in 4% paraformaldehyde for 1 h at 4 1C, and then
washed in PBS. LacZ stain solution (1 mg/ml X-gal, 5 mM K3Fe
(CN)6, 5 mM K4Fe(CN)6, 2 mM MgCl2 and 0.02% NP40) was applied
to the tissue and incubated in the dark at 37 1C until stain was
visible. Embryos from the same litter were used for each experi-
ment to control for transgene heterogeneity.
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Immunohistochemistry
Antibody stains were performed on parafﬁn sections. Tissues
were ﬁxed overnight in 4% paraformaldehyde (PFA), dehydrated by
washing through an ethanol gradient series, washed in histoclear
and embedded in wax. 4 mm sections were cut, treated with
histoclear and rehydrated through an ethanol gradient series.
Antigen retrieval was obtained by boiling the sections in citrate
buffer (0.1 M sodium citrate pH6 and 0.05% Tween). Sections were
incubated in PBS with 10% sheep serum and then incubated with
primary and secondary antibodies in PBS with 1% sheep serum.
Sections were counterstained with DAPI nuclear stain. The follow-
ing antibodies were used for immunohistochemistry; SOX9 was a
kind gift from Francis Poulat (CNRS, Montpellier, France, 1:2000),
Ki67 (clone TEC-3, Dako, 1:20), E-Cadherin (BD Transduction Labs,
1:50). Secondary ﬂuorescent antibodies were obtained from
Molecular Probes and were used at a 1:500 dilution. Fluorescent
images were visualized and collected on a Leica TCS-SP2 confocal
microscope.
Results
RA is required for the initiation of prostate development from the UGS
ALDH enzymes catalyze the ﬁnal step in RA synthesis and have
restricted expression patterns reﬂecting areas of active signaling.
The expression of the ALDH enzymes, Aldh1a1, Aldh1a2 and
Aldh1a3, in the mouse UGS has been investigated, although not
in both sexes (Vezina et al., 2008). Consistent with previous data,
whole mount in situ hybridization analysis showed restricted
expression of all three enzymes in the UGM of male embryos at
the early stages of prostate development. Interestingly, Aldh1a1
and, at a lower level, Aldh1a3 expression were sex speciﬁc in that
they were undetected in the female UGS at E15.5, while Aldh1a2
was present in both males and females (Fig. 1A–C). This sex
speciﬁcity was conﬁrmed by RTPCR (Fig. 1G–I). In the case of
Aldh1a1, we observed induction of expression in female UGS after
24 h, but not 6 or 12 h, of growth in culture in the presence of
dihydrotestosterone (DHT) (Fig. S1A, see below for organ culture
details). This suggests that induction of Aldh1a1 is not an immedi-
ate early response to androgen action on the UGS. Analysis of
sections from stained UGS showed that Aldh1a1 and Aldh1a3 had a
more peri-urethral expression pattern at the epithelial–mesench-
ymal boundary within the male UGM, while Aldh1a2 was
expressed in the outer mesenchyme in a zone that may contain
smooth muscle cells (Fig. 1D–F) (Thomson et al., 2002).
The expression pattern of ALDH enzymes in the male UGS
indicated that RA might have a role in prostate development
initiation. This was also suggested by studies performed by Vezina
et al. (2008) who showed that addition of RA to UGS cultures
grown with DHT increased the number of prostatic buds formed.
ALDH enzymes have been known to functionally compensate for
each other, therefore an in vivo gene deletion approach was not
chosen due to the low feasibility of effectively deleting all three
enzymes in the fetal UGM. Instead, we used an ex vivo organ
culture assay where UGS from E15.5 female mouse embryos were
dissected, placed on ﬁlters and grown in deﬁned media with and
without additional supplements. Addition of DHT induced visible
prostate bud formation in 2–3 days of culture and samples were
analysed after 5–6 days in culture, at a stage when fully formed
buds can be differentiated from transient structures. Whole mount
in situ hybridization on cultured female UGS showed expression of
Nkx3.1 and Sox9, early markers of prostate development, in the
nascent buds (Bhatia-Gaur et al., 1999; Thomsen et al., 2008). In
the absence of DHT, no buds or marker expression were observed.
Nkx3.1 expression, possibly marking transient prostatic bud struc-
tures, has been observed in female UGS grown in culture by others
(Allgeier et al., 2010; Keil et al., 2012), however, this was not the
case in our conditions. To conﬁrm this result we histologically
analysed sections of our samples grown in the absence of drugs
and found no evidence of bud-like structures. To determine the
role of RA, we cultured female UGS with DHT in the presence of
4-diethylamino-benzaldehyde (DEAB), a well characterised inhi-
bitor of ALDH enzymes, and these showed a severe reduction in
Nkx3.1 and Sox9 expression and bud number (Fig. 2A, see Support-
ing Fig. S2A for Sox9 expression). To establish the speciﬁcity of
DEAB action, RA was added to the media containing DEAB and
DHT and prostate bud development was seen to be activated in
these cultured organs (Figs. 2A and S2A). Therefore these data
show that RA is required for prostate development from the UGS.
To establish if RA is sufﬁcient to initiate prostate development in
the absence of DHT, we added RA to the media. Prostate bud
development was observed in these tissues after 4 days of culture,
however, the number and size of buds was considerably smaller
than tissues grown with DHT (Figs. 2B and S2B).
RA has been shown to act through RARs and the expression of
RARα, RARβ and RARγ has been observed in the mouse UGS
(Vezina et al., 2008). To investigate whether RARs were important
in prostate development, we treated female UGS with a pan RAR
inverse agonist, BMS493, in the presence of DHT. As in the case of
DEAB, BMS493 repressed prostate bud formation, albeit not as
effectively, showing that RA was acting through RARs in the UGS
(Figs. 2C and SC). To conﬁrm that the compound was acting
appropriately, we treated female UGS from RARE-LacZ transgenic
embryos expressing LacZ driven by a promoter containing RAREs
(Rossant et al., 1991). In untreated and DHT treated female UGS,
β-galactosidase staining was observed, with an increase in levels
in the DHT treated samples (Fig. 2D). This conﬁrms the presence of
active RA signaling within the UGS that is further induced by
androgens. Treatment with BMS493 and DHT showed a reduced
level of β-galactosidase staining in the UGS, reﬂecting the inhibit-
ing action of the compound (Fig. 2D). Members of the Cyp26
family of genes have been shown to restrict the pattern of active
RA during embryogenesis and expression of Cyp26a1 and Cyp26b1
have been reported in the UGS (Vezina et al., 2008). However, we
were not able to observe expression above background in the UGS
at the early stages for both these genes in either sex. Analysis of
β-galactosidase expression in male and female UGS from RARE-
LacZ embryos showed staining in both sexes. Although the stain-
ing was found to be mosaic and variable in intensity between
litters, we did observe an increase in periurethral staining in males
compared to females, consistent with the sex speciﬁc ALDH gene
expression patterns we describe above (Fig. S1B and C).
RA represses Activin signaling in the UGS
Our studies show that RA is required for the initiation of
prostate development from the UGS. Expression analysis of genes
known to be involved in embryogenesis in male and female UGS at
E16.5 identiﬁed Inhibin βA (Inhba) as being higher in female UGS
compared to male UGS at this stage (Fig. 3A). This sex difference
was conﬁrmed by RTPCR. Interestingly, expression was found to be
restricted to the mesenchyme surrounding the UGE with highest
levels in the dorsal area (Fig. 3A). Inhba encodes the βA subunit of
Activin, a member of the Transforming Growth Factor β (TGFβ)
family involved in many processes during embryonic develop-
ment. Activin A, a dimer composed of two βA subunits, has been
implicated in prostate morphogenesis and it was shown to inhibit
branching when added to organ cultures of rat ventral prostates
(Cancilla et al., 2001). To investigate the role of DHT and RA on
Inhba expression in the UGS, we analysed, by in situ hybridization
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and RTPCR, female UGS that had been incubated in RA, DHT or
DHT and DEAB (Fig. 3B). The in situ hybridization data showed that
treatment with DHT and RA led to a striking decrease in Inhba
levels, while treatment of DHT and DEAB showed the resurgence
of Inhba in a pattern similar to untreated UGS. The RTPCR studies
showed a statistically signiﬁcant decrease in Inhba expression with
RA or DHT. However, treatment with DEAB and DHT showed
variable levels of Inhba expression in the RTPCR analysis that were
not statistically signiﬁcantly different to the DHT treatment when
averaged. This difference may be due to variability in amounts of
tissue dissected, which has more impact for the RTPCR analysis, or
suggests that repression of Inhba by DHT can also occur through
other non RA dependent mechanisms. Therefore, these data
suggest that in the UGS of male embryos RA represses Inhba
expression and indicates that the inhibitory effect of DHT on this
expression is, at least partially, through its action on RA synthesis.
To investigate the functional role of Inhba we used in vivo
genetic analysis in addition to ex vivo organ culture assays. As
Inhba mutant mice that lack functional protein die within 24 h of
birth, we studied mutant embryos at E18.5 (Matzuk et al., 1995).
Strikingly, female Inhba mutant UGS at this stage contained small
epithelial buds that protrude in the surrounding mesenchyme
similar to immature buds found in male UGS (Figs. 4A and S3A,
4 out of 4 sectioned mutant female UGS showed at least one
Fig. 1. ALDH expression in the developing mouse prostate. (A)–(C) Whole mount in situ hybridization analysis of Aldh1a1, Aldh1a2 and Aldh1a3 expression in E15.5 male and
female UGS. Images are representative from 3 UGS. (D)–(F) transverse sections through E15.5 male UGS show Aldh1a1 expression in the periurethral mesenchyme, Aldh1a2
expression in the mesenchyme and Aldh1a3 expression in the dorsal and lateral periurethral mesenchyme. A black line marks the basement membrane. (G)–(I) RTPCR
conﬁrms the sex-speciﬁc expression of Aldh1a1 in E16.5 male (p¼0.0006), no difference in expression of Aldh1a2 between E16.5 male and female UGSs (p¼0.56) and
conﬁrms an increase in expression of Aldh1a3 in the E16.5 male UGS (p¼0.005) (n¼4 for each sample). Error bars¼SD. n¼Statistically signiﬁcant difference in expression
levels. e¼Epithelia, m¼mesenchyme. White lines denote planes of section. Scale bar¼10 μM. See also Fig. S1.
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prostatic bud-like structure but no buds were observed in the
5 female control UGS analysed). No buds were observed in control
female UGS. These female Inhba mutant buds expressed high
levels of Sox9 and Ki67, a marker of proliferating cells, in a similar
pattern to control male buds (Fig. 4B). This demonstrates that
mutant female UGS initiate the early stages of prostate-like
budding in the absence of Inhba. However, these structures are
smaller and fewer than observed in normal males indicating that
additional pathways, some of which probably involving andro-
gens, are required for bud elongation and growth. In complimen-
tary experiments, we treated female UGS with SB43152, an
inhibitor of TGFβ type I receptors, including the Activin type I
receptor, ALK4. In agreement with our genetic studies, after 3–4
days of culture early prostatic-like buds were observed in female
UGS treated with the inhibitor in the absence of DHT (Figs. 4C and
S3B). This phenotype was more pronounced than the effect of RA
treatment, however, the number and size of buds were generally
smaller than those derived from DHT treated female UGS (Fig. 4C).
These data are consistent with the model that Activin represses
prostate formation from the UGS and RA acts to relieve this
inhibition and allow early bud development. To determine if the
only role of RA in the UGS is to inhibit Activin signaling, we
investigated if SB43152 treatment was able to induce bud forma-
tion in female UGS treated with DHT and DEAB. Interestingly, the
Activin inhibitor did not phenocopy RA in that it was not able to
induce prostate-like tissue in the presence of DHT and DEAB
(Figs. 4D and S3C). Consistent with this result, female UGS that
had been treated with both the Activin and ALDH inhibitors in the
absence of DHT did not show prostatic-like buds (Figs. 4E and
S4D). These data therefore show that RA has additional roles to the
inhibition of Activin signaling in the induction of prostate devel-
opment from the UGS.
To investigate whether RA has a role in prostate development
after the initial steps of bud induction, we treated male UGS from
later stage (E17.5–E18.5) embryos with DHT or DHT and DEAB.
Tissues treated with DEAB showed a reduced number and smaller
Fig. 2. Retinoic acid signaling through RARs is necessary for prostatic bud initiation and can promote budding in the absence of testosterone. (A) Whole mount in situ
hybridization analysis of Nkx3.1 expression on E15.5 female UGS grown in DHT organ culture for 6 days with and without the ALDH inhibitor DEAB, and with DEAB and RA,
as indicated (n¼13). (B) Nkx3.1 expression in E15.5 female UGSs grown in organ culture for 6 days with vehicle () (n¼17), DHT (n¼15) or retinoic acid (n¼24), as
indicated. (C) Whole mount in situ hybridization analysis of Nkx3.1 expression on E15.5 female UGS grown for ﬁve days with vehicle (), DHT in the presence and absence of
a RAR inverse agonist, BMS493 (n¼8). (D) X-gal staining of E15.5 female RARE-LacZ UGS subjected to the same treatment conditions, as indicated (n¼8). See also Fig. S2.
Quantiﬁcation of bud numbers as described in the Methods and materials section is included for all treatments. n¼Statistically signiﬁcant difference in bud numbers.
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sized buds when compared to samples treated with DHT, while
samples without added compounds showed the presence of very
small buds conﬁrming that bud induction had taken place before
treatment (Fig. S4). This effect is overcome when RA is added to
media with DHT and DEAB (Fig. S4).
FGF10, which is expressed in the outer region of the UGM, is
required for the initial stages of prostate development (Donjacour
et al., 2003) and RA and FGF signaling have been shown to interact
in the morphogenesis of other organs such as the lung (Desai et al.,
2004). This suggests that FGF10 may be a target of RA signaling in
the UGS. Therefore we investigated whether RA signaling can
regulate FGF10 expression in the UGS prior to prostate budding.
However, RTPCR analysis on female UGS samples treated with RA,
DHT or DHT and DEAB showed no consistent changes in FGF10
levels (Fig. S5).
RA and DHT induce bud development in non-prostatic UGE
Prostate development occurs at the cranial end of the UGS, and
the pathways that determine this positional information have not
been determined. We noticed that the Aldh1a1 and Aldh1a2
expression patterns tended to be concentrated at the cranial portion
of the UGS (see Fig. 1A and B). Therefore we investigated the
potential of RA and/or DHT to induce prostate bud formation in
more caudal regions of the UGS. For this, we dissected and grew the
area of the male embryonic UGS found between the prostate and
the bulbourethral gland, where the epithelium is a continuous tube
and no buds are normally found (Fig. 5). Treatment of this tissue
with either DHT or RA had no effect. However, treatment with both
DHT and RA showed the formation of Sox9 and Nkx3.1 positive early
bud-like structures after 4 days in culture (Figs. 5 and S6A).
Discussion
Very little is known on how the prostate arises from the UGS in
male, but not female embryos. The central role of androgens in this
process has been known for some time, however, the mechanism
of action has not been elucidated. In this study we show that RA
signaling is required for prostate formation in both an androgen
dependent and independent manner. The expression pattern of
ALDH enzymes in the UGS and our functional studies suggest a
model where androgen action in the male leads to an increase in
RA levels in the peri-urethral region of the UGM that brings about
the decrease in levels of Inhba and therefore the relief of prostate
formation inhibition by Activin (Fig. 6). Our results are also
consistent with both RA and androgens having extra independent
roles, in addition to the regulation of Activin, in the early stages of
Fig. 3. RA represses activin signaling in the UGS. (A) Whole mount in situ hybridization analysis of Inhba shows sex-speciﬁc expression in E16.5 female UGS compared to
male. Adjacent panels, a transverse section showing Inhba expression in a female UGS and RTPCR conﬁrms the sex-speciﬁc expression of Inhba (p¼0.038). A black line marks
the basement membrane on the transverse section. (B) Top panels, whole-mount in situ hybridization analysis for Inhba expression on female E15.5 UGS organ cultures
grown for 24 h with vehicle (), DHT or RA, as indicated (n¼5). Right, RTPCR conﬁrms a decrease in Inhba expression in UGS grown 24 h in DHT or RA (no DHT v DHT
p¼0.002, no DHT v RA p¼0.020) (n¼3). Bottom panels, Inhba expression in E15.5 female UGS organ culture for 24 h grownwith vehicle (), DHT with and without DEAB, as
indicated (n¼5). Right, RTPCR analysis of Inhba expression from UGS grown 24 h with vehicle (), DHT with and without DEAB (n¼4). Error bars¼SD. n¼Statistically
signiﬁcant difference in expression levels. e¼epithelia, m¼mesenchyme.
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Fig. 4. Activin represses prostate formation and RA is required for bud outgrowth. (A) Hematoxylin and eosin stained sections of E18.5 control female UGS, Inhba mutant
female UGS and control male UGS. An arrow indicates a bud in female Inhba mutant and an arrowhead indicates a bud in control male (n¼4). Black line highlights the
epithelial-mesenchymal boundary. Quantiﬁcation of bud numbers as described in the Methods and materials section is included. (B) Immunohistochemical staining on
sections of E18.5 control female UGS, Inhba mutant female UGS and control male UGS. Top panels, staining of Sox9 (red) and E-Cadherin (green), show high levels of Sox9 in
female Inhba mutant buds (white arrow) and control male buds (white arrowhead). Bottom panels, staining of Ki67 (red) and E-Cadherin (green), show Ki67 positive cells in
female Inhba mutant buds (white arrow) and control male buds (white arrowhead). E-Cadherin staining marks the epithelial cells of the UGS. (C) Whole mount in situ
hybridization analysis of Nkx3.1 expression in E15.5 female UGS organ cultures grown for 6 days with vehicle (), with DHT or the inhibitor of TGFb type I receptors,
SB43152, as indicated (n¼5). (D) Nkx3.1 expression in E15.5 female UGS organ cultures grown in DHT for 6 days with and without DEAB and SB43152, as indicated (n¼5).
E, Nkx3.1 expression in E15.5 female UGS organ cultures grown for 6 days with SB43152, DEAB or both SB43152 and DEAB, as indicated (n¼5). Quantiﬁcation of bud numbers
as described in the Methods and materials section is included for all treatments. n¼Statistically signiﬁcant difference in bud numbers. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
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bud growth. These data identify RA as a major player in the
initiation of prostate development, together with androgens.
In vivo studies have shown that all ALDH enzymes are able to
induce RA synthesis (Fan et al., 2003). In addition, we have
observed the presence of Cyp1b1, which has been shown to
generate RA independently of ALDH (Chambers et al., 2007),
within the periurethral UGS mesenchyme of male but not female
embryos (Fig. S6B). Therefore a genetic approach to manipulate
this pathway was not feasible. Our data indicate that the ALDH1A2
present in the female UGS is not able to inhibit Inhba expression.
In contrast to previous studies (Vezina et al., 2008), we were not
able to observe signiﬁcant expression in the mouse UGS of
members of the Cyp26 family, Cyp26a1 and Cyp26b1, suggesting
that active RA is present in the female. This is in agreement with
the β-galactosidase positive staining the female UGS of the RARE-
LacZ mice (Fig. S1). Therefore our results are consistent with
amount of active RA within the UGM being important in deter-
mining the initiation of prostate development in a sex speciﬁc
manner.
Prostatic-like buds have been observed in some female UGS of
the rat (Thomson et al., 2002; Timms et al., 1999), although we
never observed this in the mice we analysed. In humans, the
female paraurethral or Skene's glands have been proposed to be
the histological homolog of the male prostate (Huffman, 1948).
Our studies suggest that investigation into the levels of RA and/or
vitamin A in the human female UGS during embryonic develop-
ment may provide information on the presence of these structures
and help explain the species difference. Our studies show that
prostate-like development occurs in UGS from Inhba mutant
female mice, and we did not observe the presence of Inhbb, which
can compensate for some aspects of Inhba function (Brown et al.,
2000). This suggests that the levels of Activin in the UGS during
embryogenesis could also affect this outcome.
The UGM has been proposed to specify prostate identity on
epithelium derived from various tissues and on embryonic stem
cells when recombined and grown as kidney grafts (Cunha et al.,
1983; Taylor et al., 2006). Androgens and AR are required for this
process, however, our studies show that DHT alone is not able to
induce bud formation at ectopic sites in the UGS but that a
combination of DHT and RA is required. ALDH expression in the
mouse UGS is concentrated in the cranial region of the UGS, where
prostate development occurs, and is highest during fetal stages
and decreases signiﬁcantly around birth. This suggests that RA
contributes to the competence of the UGM to specify prostate
formation by providing a regional and stage context.
RA signaling has been identiﬁed to be important in many
inductive processes during embryonic development. In lung mor-
phogenesis, it has been shown to inhibit TGFβ signaling in the
endodermal derived foregut to allow FGF10 expression and pri-
mary lung bud formation (Chen et al., 2007). However, Activin
expression was not investigated in this pathway and we found no
evidence of a relationship between RA and FGF10 in the UGS.
Therefore, it is likely that the downstream pathways regulated by
RA in the embryo are dependent on the tissue.
Our study identiﬁes a role for RA during the initiation of prostate
formation from the UGS. Although we observe that RA is required
for prostate growth at later stages, ALDH expression in the UGM
decreases with age. ALDH1a1 has been shown to be expressed in
adult human prostate epithelia and ALDH1a2 has been detected in
adult prostate epithelia of mouse and man (Kim et al., 2005; Li et al.,
2010; Touma et al., 2009). This suggests a complex role for this
signaling pathway as the prostate differentiates and matures.
Consistent with this, RA treatment of neonatal prostates can inhibit
morphogenesis and growth (Aboseif et al., 1997). Retinoids, includ-
ing RA, have been proposed as antitumour agents in prostate cancer
and epidemiological studies have suggested that consumption of
vegetable derived vitamin A could protect against this disease
(Pienta and Esper, 1993). However, treatment of human prostate
cancer patients with retinoids have demonstrated limited success
(Hammond et al., 2002). The data presented could inform the
understanding of the effect of retinoids in prostate cancer and
suggest that the contribution of stromal RA signaling should also be
Fig. 5. RA and DHT induce bud development in non-prostatic UGE. (A) The region of the male urethra that was dissected and grown in culture. Whole mount in situ
hybridization analysis of Sox9 expression carried out on a E18.5 prostate, urethra and bulbourethral gland (BUG). Black lines indicate the urethra. (B) Whole mount in situ
hybridization analysis of Nkx3.1 expression in male tissue dissected caudally, between the prostate and the bulbourethral gland, grown in organ culture for 6 days with DHT,
RA or both DHT and RA (n¼9). Quantiﬁcation of bud numbers as described in the Methods and materials section is included for all treatments. *¼Statistically signiﬁcant
difference in bud numbers. See also Fig. S6.
Fig. 6. Model depicting RA action in the UGS. Representation of an embryonic UGS
with epithelial (grey) and mesenchymal (red) regions. Aldh1a2 expression is shown
in the outer mesenchyme (light red) in both males and females and Aldh1a1 and
Aldh1a3 are male speciﬁc and in more peri-urethral regions (darker red). We
speculate that in the male UGS, DHT action leads to high RA levels that inhibit Inhba
expression and promote prostate budding and growth. SV¼seminal vesicle (blue).
(For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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considered to determine the full role of this important pathway in
normal and neoplastic tissue.
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